IVAX Corporation

Pharmaceutical company receives new drug approval for proprietary asthma product

Published in Medical Patent Week, December 5th, 2004

IVAX Corporation (IVX) received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for its patented HFA (CFC-free) formulation of albuterol in a metered dose inhaler (MDI) for the treatment of asthma.

The product will be marketed by IVAX' U.S. proprietary products subsidiary, IVAX Laboratories, Inc. IVAX has previously received an approvable letter from the FDA on its NDA for albuterol HFA (CFC-free) in the company's patented, breath-activated inhaler, known in Europe as Easi-Breathe.

Neil Flanzraich, vice chairman and president of IVAX Corporation, said, "Products for treating respiratory disease have become...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Week

Source: Medical Patent Week (2004-12-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry